Boston Scientific completes first commercial Farapulse cases in U.S.

Boston Scientific (NYSE: BSX) + has completed the first post-FDA approval cases in the U.S. with its Farapulse pulsed field ablation system.

In a LinkedIn post, Nick Spadea-Anello, president, Electrophysiology, Boston Scientific, announced the first commercial use for the AFib treatment. Marlborough, Massachusetts-based Boston Scientific won the approval for Farapulse last month.

In doing so, it became second company to earn an FDA nod for PFA that treats AFib. Medtronic picked up the first approval for PFA to treat paroxysmal and persistent AFib in December. Approval allows the use of Farapulse in the isolation of pulmonary veins to treat drug-refractory, recurrent, symptomatic, paroxysmal AFib.

Chief Medical Officer Dr. Ken Stein spoke to MassDevice about what’s next for Boston Scientific following its landmark approval.

“Today, physicians around the U.S. got to see and feel how this novel therapy has the potential to transform the ablation space and provide patients with a safe, effective and efficient treatment option for paroxysmal [AFib],” Spadea-Anello wrote on the social media site.

Spadea-Anello said physicians completed more than 30 commercial cases on Thursday, Feb. 15. He named Dr. Andrea Natale and his team at Los Robles, as well as Dr. Wilbur Su and Dr. Roderick Tung and their team at Banner Health, who allowed him to observe the cases.

“Thank you to every person who has contributed to make this milestone possible,” he concluded. “I look forward to continuing to work together to improve the lives of patients with paroxysmal [AFib] in the U.S. and around the world.”